黄体支持治疗 中国就医指南

Luteal phase support (LPS) is a cornerstone therapeutic strategy in reproductive medicine, specifically designed to optimize endometrial receptivity and early embryonic development during the luteal phase—the period between ovulation and menstruation or pregnancy confirmation. It is not a disease per se, but rather a targeted clinical intervention used primarily in assisted reproductive technology (ART) cycles, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), frozen-thawed embryo transfer (FET), and ovulation induction protocols. The physiological luteal phase relies on sustained progesterone secretion by the corpus luteum to maintain endometrial thickness, glandular secretory activity, vascular remodeling, and immune tolerance—essential conditions for embryo implantation and early placental development. In ART, however, this natural hormonal milieu is often disrupted: GnRH agonist/antagonist use suppresses endogenous LH surges, ovarian stimulation alters follicular dynamics, and oocyte retrieval compromises corpus luteum integrity—leading to relative or absolute luteal phase deficiency (LPD). LPD manifests as insufficient progesterone production or impaired endometrial response, increasing risks of implantation failure, biochemical pregnancy loss, and early miscarriage. Epidemiologically, up to 30–40% of fresh IVF cycles and 15–25% of FET cycles exhibit suboptimal luteal function without exogenous support. Risk factors include advanced maternal age (>35 years), high-dose gonadotropin stimulation, premature LH elevation, polycystic ovary syndrome (PCOS), history of recurrent implantation failure or early pregnancy loss, and use of GnRH antagonists or agonist triggers. While LPS itself does not cause symptoms, untreated luteal insufficiency contributes significantly to emotional distress, repeated treatment disappointment, financial strain, and diminished quality of life—particularly among individuals undergoing multiple ART cycles. Patients frequently report anxiety around cycle timing, uncertainty about pregnancy viability, and fatigue from daily injections or vaginal applications. Psychosocial impacts extend to relationship stress, work disruption, and reduced sexual well-being due to procedural demands and hormonal side effects (e.g., bloating, mood swings, breast tenderness). Evidence-based LPS typically begins shortly after oocyte retrieval or trigger administration and continues until pregnancy testing—and if positive, often through the first 8–12 weeks of gestation to bridge endogenous luteoplacental shift. Progesterone remains the gold-standard agent, delivered via vaginal micronized formulations (gel, suppositories, tablets), intramuscular injections, or oral micronized capsules—each with distinct pharmacokinetic profiles and tolerability. Adjunctive strategies may include low-dose hCG supplementation (with caution due to OHSS risk) or estradiol co-administration in specific FET protocols. Rigorous monitoring—including serum progesterone levels, endometrial ultrasound assessment, and clinical symptom tracking—ensures individualized dosing and timely intervention. As ART access expands across China, standardized, patient-centered LPS protocols are increasingly recognized as critical determinants of live birth rates and holistic care quality.

# 黄体支持治疗方案与费用明细（生殖医学科）

一、非手术/药物保守治疗（主流方案）

适用人群：IVF-ET、自然周期排卵障碍、复发性流产、黄体功能不全者。

• •口服黄体酮（地屈孕酮）：20–40元/盒（10mg×20片），日均费用约3–6元，疗程14–28天；
• •阴道用黄体酮凝胶/胶囊（雪诺同、安琪坦）：198–320元/支（90mg），日均50–85元；
• •肌肉注射黄体酮注射液（20mg/mL）：8–15元/支，含无菌注射耗材，日均12–25元；
• •配套检查费：孕酮（P）、雌二醇（E₂）、HCG血检（3项联检）120–180元/次，共2–4次。

二、微创介入/强化支持方案

适用人群：反复移植失败、内膜容受性差、高龄（≥40岁）或低反应患者。

• •个体化黄体支持联合生长激素预处理：生长激素（国产）1200–2800元/支（4.5IU），疗程3–7天；
• •宫腔灌注hCG增强黄体功能：单次操作费+药费合计800–1500元；
• •术前评估：超声子宫内膜厚度+血流检测、子宫内膜容受性芯片（ERA）检测3800–5200元。

三、复杂/耐药/并发症应对方案

• •多囊卵巢综合征（PCOS）合并黄体缺陷：加用二甲双胍+个体化剂量调整，额外药费200–500元/周期；
• •免疫因素相关黄体功能障碍：低分子肝素+泼尼松联合方案，月均药费1200–2600元；
• •严重黄体期缺陷致生化妊娠反复发生：启动DHEA预处理+胚胎植入前遗传学检测（PGT-A），总增费用12000–18000元。

方案快速选择指南

✅ 首次IVF者 → 阴道黄体酮（中档）+基础血检（预算约2500–3500元/周期）； ✅ 反复失败者 → 宫腔灌注hCG+ERA检测（预算约7000–9500元/周期）； ✅ 高龄/免疫异常者 → 全程强化方案（含生长激素+免疫调节，预算12000–22000元/周期）。